Promising Alzheimer’s drugs are
ready for late-stage clinical trials
Virtually all adults with Ds develop the neuropathology (amyloid beta plaques and tau tangles) consistent with Alzheimer’s by their 40s. At age 40, 10% already have Alzheimer’s dementia. Without necessary resources, Pharma will not be able to measure how well any therapies work for people with Down syndrome and will delay the initiation of late stage clinical trials in Down syndrome with their promising Alzheimer’s therapies.
LuMind RDS has funded a grant to support the planning effort required to establish a Down Syndrome Clinical Trial Consortium, focused initially on advancing Alzheimer’s therapies for individuals with Down syndrome.